Eqitx appoints chief executive officer
Wednesday, 01 September, 2004
Melbourne-based Equitx (ASX:EQX) has appointed former Agenix vice president Sue Parry-Jones as chief executive officer.
“Sue’s experience in new product development and commercialisation at a number of large pharmaceutical companies including Schering-Plough and Bristol-Myers Squibb, together with her biotechnology industry experience at Agenix and Amgen, have given her an ideal mix of skills to progress the development of our VacTX novel vaccine and ZingoTX Gingerol projects,” said Eqitx Chairman Mr Sol Majteles in a statement. Parry-Jones was most recently vice president of Molecular Diagnostic Imaging at Agenix.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
